GET DAILY SIGNALSGenmab (GMAB) Climbs +61% on Positive Oncology Trial Results
Key Takeaways
- Genmab (GMAB) shares climbed roughly 61% over the last 30 days, advancing from about $35.57 to near $57.28 on the strength of two late-stage oncology data readouts.
- The decisive catalyst was positive topline results from the Phase 3 LiGeR-HN1 trial, in which petosemtamab combined with pembrolizumab reduced the risk of death by 50% in first-line head and neck cancer.
- Earlier in the period, the Phase 3 RAINFOL-02 trial showed Rina-S met its primary and key secondary endpoints in platinum-resistant ovarian cancer.
- Analyst sentiment turned more constructive, including a JPMorgan upgrade to Overweight and higher price targets from other firms.
- Over the broader quarter, the stock more than doubled from roughly $28.52 as investors repriced Genmab's pipeline.
Genmab (GMAB) Company Overview and Market Position
Genmab A/S is a Copenhagen, Denmark-based biotechnology company founded in 1999 that specializes in discovering and developing antibody-based therapies for cancer and other serious diseases. Its technology platforms span bispecific antibodies, antibody-drug conjugates, and effector function-enhanced antibodies. The company's economics are anchored by royalty streams from partnered blockbusters, most notably DARZALEX (daratumumab), alongside wholly owned commercial products such as EPKINLY/TEPKINLY (epcoritamab) and Tivdak (tisotumab vedotin). A network of collaborations with major pharmaceutical partners, including Johnson & Johnson (JNJ), AbbVie (ABBV), and Pfizer (PFE), lets Genmab capture value from global commercial infrastructure while advancing a deep internal pipeline. Its late-stage priorities center on EPKINLY, Rina-S (rinatabart sesutecan), and petosemtamab, an asset added through the roughly $8 billion acquisition of Merus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Genmab (GMAB) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, GMAB advanced approximately 61%, rising from a closing price of about $35.57 to roughly $57.28. The move accelerated sharply in late October, when shares surged about 30% in a single session to an all-time intraday high of $59.97 on October 28. The rally was accompanied by unusually heavy volume of more than 19 million shares, versus a three-month daily average near 4 million.
The quarterly trend was even stronger. From a closing level of roughly $28.52 three months earlier, the stock more than doubled, gaining about 101%. This reflects a sustained repricing of Genmab's pipeline rather than a single isolated event, as investors progressively rewarded positive clinical data across multiple programs. From what I see, the volume spike on that October 28 session stands out as a clear sign of institutional interest.
What Drove GMAB Stock Price in the Last 30 Days
The primary catalyst was the October 28 announcement of positive topline results from the global Phase 3 LiGeR-HN1 trial. The study evaluated petosemtamab in combination with pembrolizumab for first-line recurrent or metastatic head and neck cancer. Initial analysis showed a statistically significant and clinically meaningful improvement in overall survival versus pembrolizumab alone, with the combination reducing the risk of death by 50% and meeting its dual primary endpoints of overall survival and objective response rate.
This news built on an earlier data catalyst. On October 23, Genmab reported that the Phase 3 RAINFOL-02 trial of Rina-S in platinum-resistant ovarian cancer met both its primary progression-free survival endpoint and a key overall survival endpoint, with the drug cutting the risk of disease progression or death by 71% compared with chemotherapy. Following these readouts, JPMorgan upgraded Genmab to Overweight from Neutral and raised its price target, while TD Cowen lifted its target and reiterated a Buy rating. Analysts also cited petosemtamab as a central long-term growth driver for the company. I’m watching this closely because the dual readouts in quick succession changed the risk profile of the pipeline in a meaningful way.
What Drove GMAB Stock Performance Over the Last Quarter
The quarterly doubling of GMAB shares reflects a broader narrative of pipeline validation and strategic repositioning. Through 2026, management has framed the year as "catalyst-heavy," with registrational readouts expected across EPKINLY, Rina-S, and petosemtamab and potential launches in 2027. The completed Merus acquisition expanded Genmab's late-stage portfolio and accelerated its shift toward a wholly owned commercial model, while the company continues to benefit from durable DARZALEX royalties and growing EPKINLY and Tivdak sales. Positive data in ovarian and head and neck cancer during the period de-risked key programs and prompted analysts to raise forward-looking peak-sales estimates, contributing to the stock's steep upward trajectory.
GMAB Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on the final analysis of the LiGeR-HN1 trial and Genmab's regulatory engagement for petosemtamab, along with the full Rina-S data set. Upcoming earnings releases, updates to 2026 guidance, and additional Phase 3 readouts for EPKINLY across earlier lines of diffuse large B-cell lymphoma will also be closely watched. Key risks include clinical or regulatory setbacks, competitive pressure in oncology, reliance on partner royalty streams such as DARZALEX, and the elevated valuation that now reflects high pipeline expectations. As with any biotechnology name, trial outcomes and regulatory decisions remain the dominant swing factors for the share price. One thing that stands out is how the recent data has shifted analyst models, and I checked this using Tickeron’s AI Trend Prediction Engine to see how models are adjusting expectations.
Exploring Tickeron AI Tools for Biotech Analysis
In my own research process, I often turn to Tickeron’s suite of AI tools when evaluating names like this one. The platform’s AI Trading Bots, for instance, help surface systematic approaches that align with different risk profiles, which can be useful when navigating volatile moves in the biotechnology sector. I find the ability to compare strategies across holding timeframes and performance metrics gives a clearer view of how data-driven models are positioning around clinical catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GMAB's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for GMAB turned positive on October 19, 2026. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +11.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 197 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 137 of 211 cases where GMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
GMAB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.914) is normal, around the industry mean (3.151). P/E Ratio (44.723) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (439.237).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.
Industry Biotechnology
Advertisement